Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

RAS-targeted therapies: is the undruggable drugged?
Amanda R. Moore, Scott Rosenberg, Frank McCormick, et al.
Nature Reviews Drug Discovery (2020) Vol. 19, Iss. 8, pp. 533-552
Open Access | Times Cited: 810

Showing 51-75 of 810 citing articles:

Ongoing Clinical Trials of Nonviral siRNA Therapeutics
Eshan A. Narasipura, Rachel VanKeulen-Miller, Yutian Ma, et al.
Bioconjugate Chemistry (2023) Vol. 34, Iss. 7, pp. 1177-1197
Closed Access | Times Cited: 42
Mechanisms of Resistance to Oncogenic KRAS Inhibition in Pancreatic Cancer
Julien Dilly, Megan T. Hoffman, Laleh Abbassi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 11, pp. 2135-2161
Closed Access | Times Cited: 36
Combinatorial strategies to target RAS-driven cancers
Naiara Perurena, Lisa Situ, Karen Cichowski
Nature reviews. Cancer (2024) Vol. 24, Iss. 5, pp. 316-337
Closed Access | Times Cited: 22
Natural products targeting the MAPK-signaling pathway in cancer: overview
Aiwen Shi, Li Liu, Shuang Li, et al.
Journal of Cancer Research and Clinical Oncology (2024) Vol. 150, Iss. 1
Open Access | Times Cited: 19
ERK pathway agonism for cancer therapy: evidence, insights, and a target discovery framework
Oleg Timofeev, Philippe Giron, Steffen Lawo, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 19
Thioredoxin (Trx): A redox target and modulator of cellular senescence and aging-related diseases
Bowen Yang, Yumeng Lin, Yibo Huang, et al.
Redox Biology (2024) Vol. 70, pp. 103032-103032
Open Access | Times Cited: 18
Targeting the undruggables—the power of protein degraders
Chao Zhang, Yongbo Liu, Guangchen Li, et al.
Science Bulletin (2024) Vol. 69, Iss. 11, pp. 1776-1797
Open Access | Times Cited: 18
The roles of KRAS in cancer metabolism, tumor microenvironment and clinical therapy
Qinglong Ma, Wenyang Zhang, Kongming Wu, et al.
Molecular Cancer (2025) Vol. 24, Iss. 1
Open Access | Times Cited: 3
Plasma membrane-associated ARAF condensates fuel RAS-related cancer drug resistance
Wen Li, Xiaoxian Shi, C. S. Tan, et al.
Nature Chemical Biology (2025)
Closed Access | Times Cited: 2
The Role of KRAS Mutations in Colorectal Cancer: Biological Insights, Clinical Implications, and Future Therapeutic Perspectives
Mitsunobu Takeda, Shoma Yoshida, Takuya Inoue, et al.
Cancers (2025) Vol. 17, Iss. 3, pp. 428-428
Open Access | Times Cited: 2
Recent Advances in Peptide Inhibitors Targeting Wild-Type Ras Protein Interactions in Cancer Therapy
Weirong Qin, Zijian Liu, Mingyu Huang, et al.
International Journal of Molecular Sciences (2025) Vol. 26, Iss. 4, pp. 1425-1425
Open Access | Times Cited: 2
Structural basis for the action of the drug trametinib at KSR-bound MEK
Z.M. Khan, Alexander M. Real, William M. Marsiglia, et al.
Nature (2020) Vol. 588, Iss. 7838, pp. 509-514
Open Access | Times Cited: 122
Allosteric SHP2 inhibitors in cancer: Targeting the intersection of RAS, resistance, and the immune microenvironment
D. Lucas Kerr, Franziska Haderk, Trever G. Bivona
Current Opinion in Chemical Biology (2021) Vol. 62, pp. 1-12
Closed Access | Times Cited: 100
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Ivana Yen, Fergus Shanahan, Jeeyun Lee, et al.
Nature (2021) Vol. 594, Iss. 7863, pp. 418-423
Closed Access | Times Cited: 93
Targeting KRAS in pancreatic cancer: new drugs on the horizon
Sahar F. Bannoura, Md. Hafiz Uddin, Misako Nagasaka, et al.
Cancer and Metastasis Reviews (2021) Vol. 40, Iss. 3, pp. 819-835
Open Access | Times Cited: 71
Selective and noncovalent targeting of RAS mutants for inhibition and degradation
Kai Wen Teng, Steven T. Tsai, Takamitsu Hattori, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 70
Drugging the Undruggable: Advances on RAS Targeting in Cancer
Míriam Molina‐Arcas, Amit Samani, Julian Downward
Genes (2021) Vol. 12, Iss. 6, pp. 899-899
Open Access | Times Cited: 68
The Importance of Being PI3K in the RAS Signaling Network
Cristina Cuesta, Cristina Arévalo-Alameda, Esther Castellano
Genes (2021) Vol. 12, Iss. 7, pp. 1094-1094
Open Access | Times Cited: 68
Strategies for targeting undruggable targets
Gong Zhang, Juan Zhang, Yuting Gao, et al.
Expert Opinion on Drug Discovery (2021) Vol. 17, Iss. 1, pp. 55-69
Closed Access | Times Cited: 66
Targeting loss of heterozygosity for cancer-specific immunotherapy
Michael S. Hwang, Brian J. Mog, Jacqueline Douglass, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 12
Open Access | Times Cited: 64
The ERK mitogen-activated protein kinase signaling network: the final frontier in RAS signal transduction
Jennifer E. Klomp, Jeffrey A. Klomp, Channing J. Der
Biochemical Society Transactions (2021) Vol. 49, Iss. 1, pp. 253-267
Closed Access | Times Cited: 63
Mechanistic insights into the effect of phosphorylation on Ras conformational dynamics and its interactions with cell signaling proteins
Yuanhao Wang, Dong Ji, Chaoyu Lei, et al.
Computational and Structural Biotechnology Journal (2021) Vol. 19, pp. 1184-1199
Open Access | Times Cited: 61
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Mingying Xie, Xiaoling Xu, Yun Fan
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 61
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges
Daolin Tang, Guido Kroemer, Rui Kang
Molecular Cancer (2021) Vol. 20, Iss. 1
Open Access | Times Cited: 61
KRAS G12D targeted therapies for pancreatic cancer: Has the fortress been conquered?
Sahar F. Bannoura, Husain Yar Khan, Asfar S. Azmi
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 61

Scroll to top